Explore the groundbreaking advancements in inhaled drug delivery, a transformative approach that promises enhanced efficacy and patient convenience

Novel technologies in drug development, including personalized medicine manufacturing, cyclic peptides, and continuous manufacturing methods.

Pfizer continues to explore even greener alternatives to traditional lyophilisation methods like air cooling in its pursuit of environmental sustainability.

Optimising drug delivery, stability, and patient outcomes through considerations such as formulation simplicity, critical temperatures, excipient selection, and the use of digital approaches.

What needs to be considered for RNA drug delivery? From the stability of LNPs, to proteins in the blood, to descant selection and packaging.

Inhaled biologics are being evaluated as an alternative to injections for treating rare and serious diseases. Experts touch on several challenges including making stable and safe formulations of inhaled biologics.

Cholesterol oxidation, working with regulators, drug loading nanoparticles, and functional excipients for specific pathways.

An expert panel of formulation scientists discuss the challenges and solutions within the formulation development for biologics.

Our discussion group on new delivery technologies considered novel and imaginative techniques for delivering drugs to their active sites.

Key opinion leaders from AstraZeneca and King’s College London present their findings on cutting-edge approaches to nano delivery.

Liquid formulations of medicines exist to serve the needs of vulnerable patients. What are their applications? And what challenges are they facing, both in industry and on the market?

Our Inhaled Therapeutics discussion group brought together key experts in the field of dry powder formulation to discuss their research into both formulation and process.

Karsten Flügel of Merck Healthcare discusses how in-silico tools are used to optimise process development for drug production.

Our expert panel discuss the process of ensuring that inhalation devices are not burdensome to use.

When designing drug-delivery devices, the patient must be at the centre of the development process. Nélio Drumond of Takeda Pharmaceuticals discusses how this patient-centric approach allows the design to maximise efficiency and efficacy.

Our Formulation discussion group this September focused on the unique challenges of developing formulations for biotherapeutics

Our panel discussion from Formulation UK 2021 highlights protein aggregation, safety, and novel technologies.

Using a combination of prevalent CSTDs with biologic molecules, we present a systematic approach to evaluate the risks and impact of CSTD to drug product quality, dose preparation, and dosing accuracy

RNA therapeutics have great potential, as evidenced by the success of Pfizer-BioNTech and Moderna’s COVID vaccines. One difficulty that may stunt their success lies in their delivery challenges.